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ABSTRACT 
Peptide antigen-presentation by Major 
Histocompatibility Class (MHC) I proteins 
initiates CD8+ T cell mediated immunity against 
pathogens and cancers. MHC I molecules typically 
bind peptides with nine amino acids in length with 
both ends tucked inside the major A and F binding 
pocket. It has been known for a while that longer 
peptides can also bind by either bulging out of the 
groove in the middle of the peptide or by binding 
in a zig-zag fashion inside the groove. In a recent 
study, we identified an alternative binding 
conformation of naturally occurring peptides from 
Toxoplasma gondii bound by HLA-A*02:01. 
These peptides were extended at the C-terminus 
(PW) and contained charged amino acids not more 
than 3 residues after the anchor amino acid at PW, 
which enabled them to open the F pocket and 
expose their C-terminal extension into the solvent. 
Here, we show that the mechanism of F pocket 
opening is dictated by the charge of the first 
charged amino acid found within the extension. 
While positively charged amino acid result in the 
Tyr84 swing, amino acids that are negatively 
charged induce a not previously described Lys146 
lift. Further, we demonstrate that the peptides with 
alternative binding modes have properties that fit 
very poorly to the conventional MHC class I 
pathway, and suggest they are presented via 
alternative means, potentially including cross-
presentation via the MHC class II pathway.  
________________________________________ 
 
Peptide presentation by MHC class I 
molecules regulates which fragments of a 
pathogen or cancer antigen are displayed to 
cytotoxic T cells for immune recognition. 
Understanding the mechanism of antigen 
presentation by MHC I is crucial in an attempt to 
 http://www.jbc.org/cgi/doi/10.1074/jbc.M117.776542The latest version is at 
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design therapeutic strategies aimed at modulating 
subsequent immune responses to control disease.  
Toxoplasmosis is a parasitic disease caused by 
infection with the large intracellular protozoan 
Toxoplasma gondii (1,2).  While generally 
asymptomatic in healthy adults, T. gondii infection 
can cause congenital toxoplasmosis during 
pregnancy and result in abortion or neonatal 
disease (1,2). T cell mediated immunity against T. 
gondii derived peptide antigens provides strong 
protection against T. gondii and involves both 
peptide presentation by Major Histocompatibility 
Class I (MHC I) and Class II (MHC II) protein (3-
5). While T. gondii can interfere with CD4 T cell 
responses by downregulating MHC II expression 
in IFN-g activated macrophages, immunization 
with T. gondii MHC II peptide ligands can elicit 
potent CD4 T cell response that can lower parasite 
burden in the brain (6,7). Immunocompromised 
individuals and patients with T-cell deficiencies 
are highly susceptible to T. gondii infections (8,9).  
CD8+ T cell responses have been studies more 
widely than CD4+ and peptide ligands for MHC I 
have been identified to be derived from surface 
proteins, or proteins of specialized secretory 
organelles (rhoptry proteins) that can either be 
secreted into the parasite cytosol or the 
parasitophorous vacuole (8-14).  
  HLA-A*02:01 has been the focus of 
studies aimed at identifying MHC-I restricted 
peptide ligands that confer protection against T. 
gondii in HLA transgenic mice (15), and as such is 
a suitable MHC class I allele to study the basic 
rules of peptide presentation. Generally, most 
canonical peptide ligands for MHC I are 9-10 
amino acids in length. However, peptide ligands 
with more than 11 amino acids have been 
identified as ligands for MHC I in general and 
form the non-canonical ligand group (13,16,17). 
These long peptides have been shown to interact 
with the residues of the binding groove of HLA 
class I heavy (alpha) chain much like the canonical 
binders with some changes. The second (P2) and 
C-terminal (PW) residues of the antigen peptide 
anchor into the A and F pockets of the binding 
groove, respectively while the middle portion of 
these over-sized peptides either ‘bulge out’ or 
‘zig-zag’ in the binding groove to be 
accommodated (18,19).     
  In contrast to these ‘bulged’ peptides, we 
had recently identified longer T. gondii peptides 
eluted from HLA-A*02:01 molecules that had a 
conserved N-terminal start but differed in their 
residue composition at the C-terminus (20). We 
showed through crystallographic studies that in the 
HLA-A*02:01 complex with one 12 mer peptide 
residue Tyr84 of the MHC heavy chain swung out 
and opened the F pocket, allowing the C-terminal 
amino acid of the peptide to protrude into the 
solvent, while the nested 11mer N-terminal core 
peptide bound in a conventional zig-zag 
orientation tucked with both peptide ends inside 
the peptide binding groove.  
 To further investigate whether the opening 
of the binding groove could be achieved with other 
peptides presented on T. gondii infected cells, and 
to understand what the structural requirements are 
to enable such unconventional modes of binding, 
we crystallized complexes of HLA-A*02:01 with 
several pairs of core (nested) and C-terminally 
extended peptides. Surprisingly, we found that that 
there are at least two distinct modes of opening the 
F pocket of HLA-A*02:01 involving the residues 
Tyr84 and Lys146. We suggest that these 
unconventional modes of binding will help better 
understand targets of MHC class I restricted 
epitope recognition.  
 
RESULTS 
Crystal structures of HLA-A*02:01 in complex 
with conventional and extended peptides 
To identify additional peptides with likely 
unconventional binding motifs, we scanned the set 
of peptides eluted from HLA-A*02:01 for those 
that had poor predicted binding affinity of the full 
length peptide (percentile rank>10%), but 
contained a nested N-terminal peptide with high 
predicted affinity (percentile rank <2%). In our 
previous study we had examined one such peptide 
(FVLELEPEWTVK) which had a single lysine 
added to the C-terminus of the core peptide 
(FVLELEPEWTV) and induced a structural 
change in Tyr84 of HLA-A*02:01 (20). In contrast, 
in the current study we examined 3 sets of the 
peptides that had C-terminal amino acid additions 
that contained negatively charged amino acids or 
both negatively and positively charged residues 
(Figure 1). To investigate if the F pocket of HLA-
A*02:01 could also be opened by these extending 
peptides, we refolded HLA-A*02:01 with several 
nested and extending peptides and determined the 
crystal structures of these complexes. We obtained 
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crystal structures for all complexes at resolutions 
between 1.85 Å and 2.75 Å (Table 1). Electron 
densities for all the peptides were well defined 
over the entire peptide length that is bound within 
the binding groove, while C-terminally extending 
residues that did not contact HLA-A*02:01 were 
disordered (Figure 1).  When all the different 
peptides are compared, slight structural changes in 
HLA-A*02:01 are observed in the A pocket. 
Peptides with an N-terminal tyrosine 
(YLSPIASPL, YLSPIASPLL, and 
YLSPIASPLLDGKSLR) open the A pocket 
slightly for the bulky side chain to be 
accommodated, while peptides that begin with 
glycine (GLKEGIPAL, GLKEGIPALDN, 
GLLPELPAV, and GLLPELPAVGGNE) are 
more buried inside the A pocket, since they lack 
any side chain (Figure 1). In addition, subtle 
structural changes are observed throughout the 
binding groove to allow optimal binding of the 
different amino acid side chains. However, when 
structures of the core peptides are compared with 
their respective extended peptides, the position of 
Tyr84 of HLA-A*02:01 was unchanged. 
Surprisingly, however, Lys146 of the F pocket, 
which is located close to Tyr84 and forms a “lid” 
to bury the PW amino acid in the core peptides 
moved upwards to open the F pocket, when the 
extending peptides were bound (Figure 1). While 
Lys146 adopts slightly different positions when all 
the extending peptide structures are compared, in 
each structure the Lys146 lid was opened for the 
C-terminal extensions to protrude from the F 
pocket. 
 
Hydrogen bond network for nested and longer 
peptide pairs 
  Next, we looked at the detailed 
interactions between HLA-A*02:01 and the 
individual peptides. In case of peptide 
GLKEGIPAL, an extensive hydrogen bond 
network is seen involving PW leucine residue and 
residues of the heavy chain that line the binding 
groove including Asp76, Thr80, Tyr84, Thr143, 
Lys1467 and Trp147 (Figure 2a. Upper panel). In 
contrast, for the extended peptide 
GLKEGIPALDN, the hydrogen bond between 
Lys146 and terminal carboxy group of PW leucine 
is replaced with one between Lys146 and the 
PW+1 aspartate side chain, since Lys146 adopts a 
different orientation (Figure 2a. Lower panel). In 
case of the peptide pair GLLPELPAV and 
GLLPELPAVGGNE, a similar hydrogen bond 
network is observed for both peptides with only a 
minor difference in the crystal structure of the 
longer peptide. The hydrogen bond interaction 
between the terminal carboxylate of PW valine and 
Lys146 is missing in the crystal structure with the 
longer peptide (Figure 2b). The same is true for 
the peptide pair YLSPIASPL and 
YLSPIASPLLDGKSLR (Figure 2c). As a result, 
the change in the orientation of Lys146 leads to 
the loss of hydrogen bond formation with the 
carboxylate of the PW amino acid. However, the 
hydrogen bond interaction between HLA-A*02:01 
residue Trp147 and the backbone oxygen of the P8 
amino acid remains conserved. Depending on the 
amino acid following residue P8 a novel hydrogen 
bond can be formed with the side chain of a 
compatible amino acid at PW+1 (here Asp10). 
Since the C-terminally extending amino acids 
project away from the peptide binding groove, 
electron density becomes increasingly disordered 
as the peptide exits the F pocket (Figure 1).  
 
Extending peptides do not significantly destabilize 
HLA-A*02:01  
  To determine the relative stability of the 
individual HLA-A*02:01-peptide complexes, we 
followed their thermal denaturation by differential 
scanning fluorimetry. The melting temperatures 
(Tm) obtained from the melt curves allowed us to 
compare the stability of the different complexes 
(Figure 3). We observe that complexes of HLA-
A*02:01 with extended peptides had similar 
stability to those with their equivalent nested 
peptides with not more than 8°C difference 
between them. For example, the Tm for HLA-
A*02:01 complex with GLKEGIPAL is 63°C 
while that with its longer peptide counterpart is 
61°C. Addition of 6 extra residues to peptide 
YLSPIASPLL also only changes the Tm of the 
complex with peptide YLSPIASPLLDGKSLR by 
about 7°C [Figure 3 and ref. (20)]. Interestingly, 
some of the complexes with nested peptides are as 
stable as those with longer peptides (compare 
GLKEGIPAL with GLLPEPPVGGNE, Figure 3). 
It is also worth noting that there are some 
variations in the stability of complexes with 
different nested peptides. For instance, peptide 
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GLKEGIPAL forms a less stable complex as 
compared to peptide GLLPELPAV (Figure 3). 
Although most interactions between HLA-
A*02:01 and the peptides are conserved there is a 
significant difference in the hydrogen bond 
interaction between Tyr84 with their terminal 
corboxylate (3.65 Å for G9L and 2.9 Å for G9V, 
Figure 2). The lack of an intimate hydrogen bond 
interaction of the terminal amino acid with Tyr84 
in G9L peptide is likely a major contributor to the 
reduced melting temperature. Compared to our 
previous study, we noticed that a single positively 
charged amino acid addition (compare 
FVLELEPEWTV and FVLELEPEWTVK ref. 
(20)) destabilizes the protein-peptide complex 
more than extending peptides that follow a short (2 
amino acid) negatively charged residue addition 
(compare GLKEGIPAL with GLKEGIPALDN, 
Figure 3). However, longer peptide additions (4-6 
amino acids) that contain a negatively charged 
amino acid (YLSPIASPLL vs. 
YLSPIASPLLDGKSLR and GLLPELPAV vs. 
GLLPELPAVGGNE) reduce the protein-peptide 
complex to the same extend as the single “K” 
addition found in peptide FVLELEPEWTVK (20). 
This highlights that the structural change involving 
Tyr84 of HLA-A*02:01 is more destabilizing than 
that of Lys146, when the negatively charged 
peptide extension is very short.  
 
Lysine 146 lift 
The different orientations of Lys146 upon 
binding of the longer peptides open the F pocket 
of HLA-A*02:01 and are required for the C-
terminally extending amino acids to project into 
the solvent, since Lys146 forms a partial “lid” 
above the F pocket, held in position by the 
hydrogen bond interaction of the carboxylate of 
the C-terminal amino acid (PW) of any nested 
peptide (Figures 2 and 4). Even though, the 
position of Lys146 is not precisely conserved 
between the different structures of HLA-A*02:01 
bound to the extending peptide, the lift of the 
residue to accommodate the peptide extension 
seems to be consistent. In case of the crystal 
structure of HLA-A*02:01 with YLSPIASPL, 
YLSPIASPLL, and YLSPIASPLLDGKSLR there 
are variations in the way that the two nested 
peptides are accommodated in the binding groove. 
With YLSPIASPL, the binding of the residues is 
quite conventional with the P2 and PW anchor 
residues binding to the A and F pocket. 
Surprisingly, however, YLSPIASPLL, the nested 
peptide with one extra leucine residue at the C-
terminal end of the peptide undergoes certain 
extent of bulging to accommodate the terminal 
leucine residue (PW+1, instead of PW) as the 
anchor residue in the F pocket (Figure 4d). The 
difference in the binding of these two nested 
peptides to HLA-A*02:01 underscores the 
requirement for a sequence motif or particular 
amino acid features within the bound peptide to 
induce movement of Lys146 to open the F pocket. 
Since a mere increase in length of the peptide does 
not cause the change in orientation of Ly146, it is 
likely that the addition of charged residues within 
the C-terminal extension is the contributing factor 
to open the F pocket. Thus, in addition to the 
previously identified “Tyr84 swing” to 
accommodate the peptide FVLELEPEWTVK 
(UFP16-27) (20), we observed a “Lys146 lift” in 
HLA-A*02:01 as a second mechanism of opening 
the F pocket induced by the extending peptides 
YLSPIASPLLDGKSLR, GLKEGIPALDN and 
GLLPELPAVGGNE (Figure 5). 
 
It’s a game of charge 
The negatively charged amino acids in the 
extended peptides do not always immediately 
follow the nested conventional PW anchor residue, 
but can be several residues downstream (Figure 
5c). The previously reported longer peptide 
contains a C-terminal addition of a positively 
charged residue (FVLELEPEWTVK) that opens 
the binding groove using the “Tyr84 swing” 
mechanism. Here, we observed that all extended 
peptides with a negatively charged residue only 
open the binding groove using the “Lys146 lift“-
mechanism. This included the peptide 
YLSPIASPLLDGKSLR which contains a lysine 
(positive charge) residue following the aspartate 
(negative charge), but no “Tyr84 swing” was 
observed. This suggested that the first charged 
residue determined which of the two distinct 
structural modes of binding an extended peptide 
will adapt.  
 
Extensions with negative charges are longer and 
more frequent than extensions with positive 
charges  
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Given the discovery of several ligands 
binding in an unconventional mode, we aimed to 
assess the generality of these findings. In the T. 
gondii peptide elution dataset, a total of 134 
peptides were predicted to bind with conventional 
P2-PΩ anchors with predicted rank ≤ 10%. Of the 
remaining 150 peptides with poor predicted 
binding, 108 contained a nested strong binder 
(rank ≤ 2%) at the N-terminus, with one or more 
residues extending beyond PΩ. These 108 peptides 
are expected to be enriched for examples with a 
similar unconventional mode of binding as the 
ones in our structural studies.  
We classified the ligands into having 
‘negative’ or ‘positive’ extension based on the first 
charged residue found after the nested binding 
peptide. Nearly half of the extended ligands 
contained a negatively charged residue as the first 
charged amino acid within the first three residues 
of the extension, whereas positively charged 
extensions were less frequent (Figure 6a). Positive 
extensions were short (less than 3 residues on 
average), while negative extensions had an 
average length of 8.7 residues (Figure 6b). 
Notably, 66% of the positive extensions consisted 
of a single or two residues, compared to only 8% 
of negative extensions being shorter than three 
amino acids. Considering only the longest version 
of ligands with extensions of multiple sizes, the 
average length of negative extensions was of 11.0 
residues.  
Extended peptide MHC-I ligands show a putative 
processing motif that is more similar to MHC 
class II ligands than conventional MHC-I ligands  
Given the unconventional length and 
mode of binding of the observed extended 
peptides, and given that T. gondii has an unusual 
compartmentalized lifecycle in the cells it infects, 
we wanted to examine if the unconventional 
ligands found had the typical motifs of peptides 
derived from the conventional MHC class I 
processing and presentation pathway. As shown in 
Figure 6, this was not the case. Extended ligands 
had significantly lower scores for TAP transport 
(Figure 6c) compared to canonical T. gondii 
ligands (p=1.2*10-5, Wilcoxon rank-sum test), but 
not significantly different from those of random 
peptides (p=0.34). Similarly, proteasome cleavage 
scores (Figure 6d) for extended ligands were 
significantly lower compared to canonical ligands 
(p=5*10-16), but not significantly higher than the 
random natural peptides (p=0.24). In other words, 
long ligands with terminal extensions were 
predicted to be poor substrates both for 
proteasome cleavage and TAP transport, 
suggesting an alternative mechanism for the 
generation and translocation to MHC class I of 
these extended ligands. 
Given the lifecycle of T. gondii, it is 
possible that the unconventional MHC-I peptide 
ligands derived from it are processed and (cross-
)presented through the same pathway as MHC-II 
ligands. If that is the case, we would not only 
expect that these ligands have different amino acid 
motifs as those found for MHC-I ligands (as was 
shown above), but also that they have a pattern 
congruent with what is found for MHC-II ligands. 
Accordingly, we examined the amino acid patterns 
of the C-terminal residues in extended ligands. 
Remarkably, despite being predominantly 
negatively charged or uncharged in the first 3 
residues of the extension, a large fraction of 
ligands presented either an Arginine or Lysine at 
the very C-terminal residue (42 out of 108). If 
these ligands were cross-presented, we would 
expect similar trimming motifs in class II ligands, 
and we examined published datasets of MHC-II 
ligands for evidence of such a motif (see 
Experimental Procedures). Indeed, we found that 
the C-terminal composition of the extended T. 
gondii class I ligands strongly correlated to the 
residue distribution at the C-terminus of eluted 
MHC class II ligands, where positively charged 
amino acids were also enriched (Figure 6e). Taken 
together, we find that the unconventional MHC-I 
ligands presented by T.gondii have sequence 
motifs much more consistent with cross-
presentation rather than with generation through 
proteasomal cleavage and TAP transport.   
DISCUSSION 
ab T cell receptor (TCR) recognition of 
MHC presented microbial peptides initiates T cell 
mediated immunity against infection. Generally, 
the TCR binds with both TCR a and b chain in a 
diagonal orientation above the MHC molecule 
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(28). While the germline encoded complementary 
determining region (CDR) 1 and 2 loops bind to 
MHC, the hypervariable loops CDR3a and 
3b specifically bind and recognize the peptide and 
provide antigen specificity (21).  MHC I has a 
closed binding groove and peptides bind with both 
ends tucked inside the binding pocket, while MHC 
II has an open binding pocket and peptide ligands, 
typically 15-20 amino acids bind with both N- and 
C-termini hanging over the end of the groove. 
Since MHC I presents peptides in a more confined 
space compared to MHC II, the TCR of CD8+ T 
cells often contact and discriminate their entire 
peptide sequence (21). In our present study, we 
have focused on a panel of C-terminally extended 
T. gondii peptides that contain a negatively 
charged amino acid within their C-terminal 
extensions. Analysis of a large dataset of HLA-
A*02:01 eluted T. gondii peptides from our 
previous study (20), demonstrated that C-
terminally extending peptides are very common in 
T. gondii and that additions that contain negatively 
charged amino acids are more represented than 
those that contain only positively charged residues.  
These peptides contain a canonical HLA-
A2*02:01 binding motif at their N-terminus, while 
addition of the C-terminal extensions render 
predictions about their binding to MHC I difficult. 
While the N-terminus of these peptides bind like 
canonical peptides to the MHC I allele HLA-
A*02:01, the C-terminal extensions induce a 
structural change at the F pocket to allow their 
extension into the solvent. As such, algorithms 
aimed at predicting peptide binding to MHC I 
need to capture rules that allow identification of a 
canoncial N-terminal MHC I binding motives, 
while adding descriptors, such as charged residues 
in the C-terminal extension to predict binding of 
C-terminally extending peptides. In principle these 
rules could be learned directly from peptide 
binding data using machine-learning techniques 
such as the recently described extended NNalign 
method (22,23). However, this is complicated by 
the very limited amount of quantitative data 
available characterized by non-canonical binding. 
We would envision this situation to change as 
more binding data becomes available and as MHC 
ligand data are included into the training data of 
MHC class I binding prediction algorithms. We 
showed that only charged residues that follow the 
P9 amino acid of a canonical peptide within 3 or 
less amino acids induce the structural change that 
allows them to bind to MHC I and stabilize the 
complex. These rules can now be incorporated into 
existing algorithms to predict MHCI binding 
peptide at least for HLA-A*02:01.  
Since the residues that are involved in the F pocket 
opening (Tyr84 and Lys146) are conserved across 
all HLA-A, -B, and -C alleles (and also found in 
many non-classical MHC I molecules, such as 
HLA-E, HLA-G, Qa-1, as well as viral MHC I 
mimics such as UL18), we postulate that the 
ability to open the F pocket is a universal 
characteristic found across many MHC I 
molecules. While it is not clear to what extend this 
structural change affects CD8+ T cell recognition, 
Killer Immunoglobulin Receptors (KIRs), a family 
of activating and inhibitory receptors expressed on 
NK cells, NKT cells and many CD4+ and CD8+ T 
cells, bind directly above the F pocket. As a 
consequence, any structural change around the F 
pocket would likely affect KIR binding and 
directly modulate host immune responses (24,25) 
Especially the inability of inhibitory KIRs to 
engage MHC I would lower the threshold of 
activation for many more immune cells to combat 
infection or cancers. Future studies will have to 
address the origin and potential function of these 
longer peptides in host immunity. 
 
 
EXPERIMENTAL PROCEDURES 
           HLA-A*02:01 Expression and Purification-  
HLA-A*02:01 class I heavy chain ectodomain 
(residues 21-274) and human β-2 microglobulin 
(hβ2m, 1-99) were expressed as inclusions bodies 
and refolded as reported previously with 
modifications reported here.  Briefly, both the 
heavy chain and light chain were expressed in 
Escherichia coli BL21 DE3 cells, induced at 
OD600 of 0.6 with 1mM isopropyl-1-thio-D-
galactopyranoside (IPTG) and cells were 
harvested after 4 hours by centrifugation (5000 g 
for 20 mins). Cells were resuspended separately in 
lysis buffer (100 mM Tris-HCl pH 7.0, 5mM 
EDTA, 5mM DTT, 0.5mM PMSF) and the cells 
were broken the cells were broken with 4-5 passes 
through a microfluidizer (20 kPa) (Microfluidics). 
Cell lysate was centrifuged (50,000 g for 30 min at 
4°C) to collect inclusion bodies. Inclusion bodies 
were further resuspended in wash buffer A (100 
mM Tris-HCl pH 7.0, 5 mM EDTA, 5 mM DTT, 2 
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M Urea, 2 % w/v Triton X-100) centrifuged again 
and washed in wash buffer B (100 mM Tris-HCl 
pH 7.0, 5 mM EDTA, 2 mM DTT). Finally the 
inclusion bodies were denatured in extraction 
buffer (50 mM Tris-HCl pH 7.0, 5 mM EDTA, 2 
mM DTT, 6 M Guanidine-HCl) for subsequent 
refolding. 3 mg of hβ2m was added dropwise to 
250 mL of refolding buffer (0.1 M Tris-HCl pH 
8.0, 2 mM EDTA, 400 mM L-arginine, 5 mM 
oxidized glutathione, 5 mM reduced glutathione) 
and stirred for 1-2 hours. Between 11-15 mg of 
HLA-A heavy chain mixed with 2-3 mg of 
individual peptide (GenScript) was then added to 
the refolding mix and further stirred at 4°C for 72 
hours. Final heavy chain:light chain:peptide ratios 
were in the range of 2:1:12 and 2.5:1:12 for 
different peptides. Following refolding, the 
refolding mixture was centrifuged at 50,000 g to 
remove any precipitated protein and the 
supernatant was concentrated to about 3 ml for 
size exclusion chromatography (SEC) using a 
Superdex S200 HR16/60 gel filtration column pre-
equilibrated with SEC buffer (20 mM Tris-HCl pH 
7.5, 150 mM NaCl). Fractions containing refolded 
HLA-A*02:01-b2m-peptide complexes were 
pooled, concentrated to 5-12 mg/mL and used for 
subsequent crystallization experiments.    
Crystallization and Data Collection-Initial 
attempts to obtain crystals for the HLA-A*02:01-
peptide complexes using factorial screens were not 
successful. Thin needle shaped sea urchin crystals 
of HLA-A*02:01-F12K complex obtained in 1.2M 
sodium citrate were used to cross seed the other 
complexes. The complexes were equilibrated in 
30% PEG 4000, 0.1M Tris-HCl pH 8.0, 0.2M 
lithium sulfate for 1-2 hours by mixing 0.15 µl 
complex and 0.15 µl of precipitant at 20°C before 
seeding. Thin plate-like crystals were obtained by 
sitting drop vapor diffusion at 20°C after 2-4 days. 
The crystals were flash frozen in cryoprotectant 
(crystallization solution: 100% glycerol - 3:1) 
using liquid nitrogen. 
    Diffraction data for HLA-A*02:01 complex 
with peptides G9V, G11N, G13E and Y16R were 
collected remotely at beamline 7.1 at the Stanford 
Synchrotron Radiation Light source (SSRL) and 
processed to 1.86 Å, 2.3 Å, 2.1 Å and 2.4 Å 
resolution, respectively using HKL2000. 
Diffraction data for HLA-A*02:01 complex with 
peptides G9L, Y9L and Y10L were collected 
remotely at beamline 12.3.1 at the Advanced Light 
Source (ALS) and processed to 1.85 Å, 2.5 Å and 
2.75 Å resolution, respectively using HKL2000. 
Phases were obtained by molecular replacement 
with Phaser MR (26) in ccp4i (27,28) using the 
protein coordinates for HLA-A*02:01 (PDB ID 
3MRE) and resulted in unambiguous electron 
density for all the peptides. Model building was 
carried out using COOT (29,30). Structures were 
refined using Refmac (31). Data collection and 
structure refinement parameters are provided in 
Table 1.  
Thermal Denaturation Assay-HLA-
A*02:01-b2m-peptide complexes with the various 
different peptides were analyzed for thermal 
denaturation by differential scanning fluorimetry 
using a LightCycler 480 (Roche). HLA-A*02:01-
b2m-peptide complexes with different peptides at 
100µM in reaction buffer (20mM Tris-HCl pH 7.5, 
150mM NaCl) were used as stock solutions. Each 
reaction mixture constituted of 1-2µl protein 
complex stock solution, 2µl of SYPRO Orange 
dye (100X, Invitrogen) made up to 20µl in 
reaction buffer in a 96-well white plate compatible 
with the instrument. A temperature gradient from 
20°C - 85°C at steps of 0.06°C/sec and 10 
acquisitions/°C was used for the experiment. Each 
experiment with individual protein-peptide 
complex was repeated thrice. A melt curve of the 
total fluorescence of the run was plotted against 
temperature. The minima of the first derivative of 
the melt curve from raw fluorescence data 
(temperature differential of absolute fluorescence 
versus temperature) provided the meting 
temperature (Tm) for individual HLA-A*02:01-
b2m peptide complexes (inflection point of the 
melt curve) (32). 
Binding affinity predictions and analysis 
of extensions-Binding affinities for all 284 eluted 
ligands to HLA-A*02:01 in the McMurtrey data 
set (20) were predicted using NetMHCpan-3.0 
(21). Peptides with conventional P2-PΩ anchors 
and predicted rank of up to 10% were considered 
as canonical binders. A rank score lower than 10% 
indicates that a peptide is among the 10% 
strongest binders for HLA-A*02:01 in a large pool 
of random natural peptides. Peptides that were not 
predicted to bind canonically, but containing a 
nested 8-11mer subsequence with predicted high 
affinity (rank within top 2%) at the N-terminus 
were classified as extended peptides. Extensions 
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following the PΩ of unconventional binders were 
categorized based on the first charged residue of 
the extension found within the first 3 residues of 
the extension. Extensions where the first charged 
residue was an R or K were classified as ‘positive’, 
while extensions where the first residues was a D 
or E were considered ‘negative’. As controls, we 
randomly picked amino acid sequences from the 
same set of source proteins, with the same length 
distribution as the observed extensions. We 
repeated the sampling for random extensions a 
thousand times to be able to calculate distributions 
and compared them to the observed extensions. 
Derivation of a MHC-II processing motif 
based on published data-A large set of 16,868 
unique eluted HLA class II ligands was 
downloaded from the IEDB (33) and inspected for 
amino acid enrichment at the C-terminus. We 
compared the frequency of the very last residue at 
the C-terminus in the MHCII ligands and in the T. 
gondii ligands, applying a pseudo-count correction 
(34) with β=50. Pseudo-counts exploit information 
about amino acid similarity to smooth the 
observed amino acid frequencies of small 
sequence data sets. This correction has a negligible 
effect on the large set of MHC II ligands, but it is 
important in the T. gondii dataset because some 
amino acids were never observed at the C-
terminus. Enrichment scores were then calculated 
as SA = log2(fA/qA), where fA is the pseudo-count 
corrected frequency for amino acid A, and qA is 
the background frequency of A in natural proteins. 
Prediction of proteasomal cleavage and 
TAP transport-Predictions of proteasomal 
cleavage and TAP transport were obtained using 
the MHC class I processing tools of the IEDB 
(35,36) both for ligands predicted to bind 
canonically and in the extended mode. For the 
processing predictions, precursors for all ligands 
were obtained by elongating them by one residue 
at the N-terminus (to allow for transport of 
elongated precursors by TAP) and five residues at 
the C-terminus (to cover the residues thought to 
impact cleavage by the proteasome), using the 
context of their source protein. As a control, we 
also produced proteasome and TAP scores for 100 
random natural sequences extracted from Uniprot 
(http://uniprot.org). 
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TABLE 1. Data collection and refinement statistics 
 
HLA-A*02:01 
 Peptide 
(PDB ID) 
 
 
G9L 
(5ENW) 
 
 
G11N 
(5F7D) 
 
 
G9V 
(5FA3) 
 
 
G13E 
(5EOT) 
 
 
Y9L 
(5F9J) 
 
 
Y10L 
(5FDW) 
 
 
Y16R 
(5FA4) 
Data collection        
Resolution range (Å)a 50.0-1.85 
(1.89-1.85) 
50.0-2.30 
(2.38-2.3) 
51.6-1.86 
(1.89-1.85) 
40-2.10 
(2.18-2.10) 
50.0-2.5 
(2.59-2.5) 
50-2.7 
2.8-2.7 
50.0-2.4  
(2.44-2.4) 
Completeness (%)a 93.2 (96.1) 96.6 (81.1) 98.8 (97.5) 99.6 (97.9) 100 (100) 93.4 (95.4) 97.9 (85.2) 
Number of unique 
reflections 
35,425 19,954 37,513 26,570 15,320 11,732 17,776 
Redundancy 2.7 3.4 3.7 3.6 3.7 2.8 3.4 
Rsym (%) 8.6 (53.1) 7.1 (33.5) 7.8 (31.1) 12.8 (57.0) 16.1 (71.1) 19.0 (66.4) 13.5 (66.3) 
Rpim (%) 6.1 (38.5) 4.5 (21.7) 4.7 (18.8) 7.8 (37.7) 9.7 (42.9) 13.1(45.4) 8.4 (42.6) 
I/sa 21.5 (3.1) 21.2 (3.3) 20.3 (4.6) 13.3 (2.1) 7.9 (2.1) 8.3 (2.4)  11.3 (1.7) 
        
Refinement 
statistics 
       
Number of 
reflections (F>0) 
33,590 18,963 35,290 25,169 14,464 11,305 16,851 
Maximum resolution 
(Å) 
1.85 2.3 1.86 2.1 2.51 2.7 2.4 
Rcryst (%) 20.8 (25.1) 20.9 (36.9) 20.9 (23.9) 20.9 (30.8) 19.9 (26.3) 21.3 (24.3) 20.4 (35.5) 
Rfree (%) 24.4 (29.4) 25.7 (34.1) 23.4 (29.4) 23.7 (31.3) 27.5 (33.3) 28.5 (32.9) 25.8 (36.3) 
        
Number of atoms 3371 3151 3397 3227 3170 3142 3210 
Protein 3047 3011 3060 3015 3012 2996 3032 
Peptide 
Glycerol 
62 
3 
70 
2 
59 
3 
66 
0 
67 
3 
75 
1 
77 
2 
Solvent molecules 
(waters) 
241 57 280 143 71 62 83 
Ion        1 
Ramachandran 
statistics (%) 
       
Favored 98.7 97.6 98.7 98.9 97.6 96.0 97.9 
Outliers 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
        
R.m.s.d. from ideal 
geometry 
       
Bond length (Å) 0.0064 0.0075 0.0061 0.0076 0.01 0.01 0.009 
Bond angles (°) 1.12 1.22 1.11 1.22 1.45 1.46 1.33 
        
Average B values 
(Å2) 
       
Protein 29.6 48.5 15.1 27.5 26.3 20.8 36.9 
Peptide 17.8 48.2 13.0 26.2 25.8 26.3 28.8 
Water molecules 29.4 41.7 24.8 26.7 21.0 15.8 35.2 
        
 aNumber in parenthesis refer to highest resolution shell 
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FIGURE LEGENDS 
 
FIGURE 1. HLA-A*02:01-peptide structures.   a) Overall structure of HLA-A*02:01 with heavy chain 
in gray and light chain (b2M) in blue. Peptide backbones are superimposed within the binding groove. b-
d) Molecular surface representation of the binding groove of HLA-A*02:01 with the individual peptides 
bound. Peptide sequences are labeled and charged amino acids are colored in Blue (positive) and red 
(negative). 2FoFc Electron density for the peptide (shown in blue mesh) is contoured at 1s. 
 
FIGURE 2. Detailed hydrogen bond interactions around the F pocket. HLA-A*02:01 is shown in 
grey, peptides in color and electron density for Lys146 as a blue mesh contoured at 1 s. Hydrogen bonds 
between 2.5-3.65 Å are shown as blue dashed lines. Structures of nested peptides are shown in the top 
panel and the corresponding extending peptides below. a) Peptide pair GLKEGIPAL (green) and 
GLKEGIPALD (cyan); b) GLLPELPAV (pink) and GLLPELPAVGGNE (grey); c) peptide pair 
YLSPIASPL (violet) and YLSPIASPLLDGKSLR (orange).  
 
FIGURE 3. Thermal Denaturation assay. First derivative of the melt curve for individual HLA-
A*02:01-peptide complex. Calculated melting temperatures for each complex are provided in parenthesis.  
 
FIGURE 4. Binding comparison between nested and extending peptides. a) Binding groove of HLA-
A*02:01 with the nested peptide GLKEGIPAL (green) superimposed with extended peptide 
GLKEGIPALD (cyan). b) Superimposition of nested peptide GLLPELPAV (pink) with extended peptide 
GLLPELPAVGGNE (grey). c) Superimposition of nested peptide YLSPIASPL (violet) with extended 
peptide YLSPIASPLLDGKSLR (orange). d) Superimposition of nested peptide YLSPIASPL (violet) 
with nested peptide YLSPIASPLL  (yellow). 
 
FIGURE 5. Mechanisms of F pocket opening and peptide sequences. a) ‘Tyrosine swing’: Y84 adopts 
a different rotamer to open the F pocket and accommodate longer peptide FVLELEPEWTVK (UFP16-27) 
(15). b) ‘Lysine lift’: Lifting of residue K146 to accommodate longer peptides including GLKEGIPALD, 
GLLPELPAVGGNE and YLSPIASPLLDGKSLR. c) List of nested and longer T. gondii peptides. 
Positively charged residues (blue) open the F pocket via the ‘Tyrosine swing’, while negatively charged 
residues (red) open the biding groove via the ‘ Lysine lift’.  
 
FIGURE 6. Properties of ligands with C-terminal extensions. a) Negatively charged extensions (D,E) 
in the T. gondii eluted set were more frequent than expected compared to a background distribution of 
resampled control datasets, whereas positively charged extensions (R,K) were less frequent. b) Positive 
extensions were on average shorter than 3 residues, negative extensions had a mean length larger than 8 
residues. c) TAP transport scores for extended ligands were significantly lower than for canonical ligands, 
and not significantly different from random. d) Proteasome cleavage scores for extended ligands were 
significantly lower than for canonical ligands, and not significantly higher than random. e) The C-
terminal composition of T. gondii ligands correlates with the C-terminal enrichment of class II ligands, 
with positively charged residues in the first quadrant and hydrophobic amino acids dominating the third 
quadrant. 
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Figure 1
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Figure 3 
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Figure 5 
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Figure 6 
 
 
 
 
 
d. c. 
●
●
●
TA
P 
sc
or
e
−1.0
−0.5
0.0
0.5
1.0
1.5
Ca
non
ica
l
Ex
ten
ded
Ra
ndo
m
Pr
ot
ea
so
m
e 
sc
or
e
0.5
1.0
1.5
2.0
Ca
non
ica
l
Ex
ten
ded
Ra
ndo
m
a. 
●
●
● ●
●●
●
●
●
Neg Pos
T. gondii ligands
Fr
eq
ue
nc
y o
f e
xte
ns
ion
 ty
pe
0.0
0.1
0.2
0.3
0.4
0.5
0.6
●
●
D,E
K,R
          b. 
●
●
●●●
●
●
●●
Neg Pos
T. gondii ligands
M
ea
n 
ex
te
ns
ion
 le
ng
th
2
4
6
8
10
12
14
●
●
D,E
K,R
−3 −2 −1 0 1 2 3
−3
−2
−1
0
1
2
3
T. gondii class I ligands
IE
DB
 cl
as
s I
I li
ga
nd
s
A
C
D
E
F
GH
I
K
L M
N
P
Q R
ST
V
WY
R2  = 0.491
e. 
 at D
EF Consortium
 - D
anm
arks Tekniske Inform
ationscenter on M
arch 28, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
McMurtrey, William Hildebrand, Bjoern Peters and Dirk M. Zajonc
Soumya G. Remesh, Massimo Andreatta, Ge Ying, Thomas Kaever, Morten Nielsen, Curtis
histocompatibility (MHC) class I allele HLA-A*02:01
Breaking confinement: unconventional peptide presentation by major
 published online February 8, 2017J. Biol. Chem. 
  
 10.1074/jbc.M117.776542Access the most updated version of this article at doi: 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
  
 http://www.jbc.org/content/early/2017/02/08/jbc.M117.776542.full.html#ref-list-1
This article cites 0 references, 0 of which can be accessed free at
 at D
EF Consortium
 - D
anm
arks Tekniske Inform
ationscenter on M
arch 28, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
